TY - JOUR T1 - High-dose insulin infusion in patients with COVID-19 JF - BMJ Open Diabetes Research & Care JO - BMJ Open Diab Res Care DO - 10.1136/bmjdrc-2021-002415 VL - 9 IS - 2 SP - e002415 AU - Brandon Del Carpio AU - Joseph Trang AU - Megan Vallejo AU - Michael Nimeh AU - Jinjoo Lee AU - Kelly Rafferty AU - Jordan Messler Y1 - 2021/11/01 UR - http://drc.bmj.com/content/9/2/e002415.abstract N2 - To the editor,The SARS-CoV-2, which causes COVID-19, has resulted in over 100 million cases of infection and more than 2 million deaths globally, as of February 2021. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including increased risk of severe illness or death.1 One observational study described glycemic and clinical outcomes in 1122 patients with and without diabetes and/or acute uncontrolled hyperglycemia in 88 US hospitals. Among 570 patients who expired or were discharged, the mortality rate was 28.8% in 184 patients with diabetes and/or uncontrolled hyperglycemia, compared with 6.2% of 386 patients without diabetes or hyperglycemia (p<0.001).2This promoted a review of patients positive for COVID-19 requiring ≥100 units/hour of continuous intravenous insulin infusion (CIVII) admitted to our institution, a 1368-bed comprehensive quaternary care mixed academic/community referral center between 1 March and 30 April 2020. When reviewing patients, data collected included age, gender, weight, body mass index (BMI), medical history, and … ER -